A llogeneic HSC transplant is the only curative therapy for numerous hematologic malignancies. Unfortunately 30 to 40% of patients will not have a human leukocyte antigen (HLA)-identical donor and will be excluded from therapy (1) . Cord blood (CB) transplants offer several advantages, namely, the reduced need for HLA matching [thereby extending transplantation availability to nearly all patients (2) ] and the decreased risk of chronic graft-versus-host disease, the most important determinant of long-term quality of life in transplant patients. However, CB transplants suffer from limited progenitor cell dose, leading to delayed neutrophil engraftment and increased mortality (3, 4) .
Recent studies in immunodeficient mice have confirmed the existence of human CB-derived long-term-repopulating hematopoietic stem cells (LT-HSCs) capable of regenerating the lifelong production of all mature blood cells (5) . These LT-HSCs show a delayed engraftment pattern, in opposition to short-term HSCs (STHSCs) that produce short-lived progenitors responsible for the production of mature blood cells and prompt neutrophil recovery (3, 5) . Hence, there is great interest in the development of conditions for robustly expanding these progenitor cells while maintaining or expanding LT-HSCs. Unfortunately, most expansion systems available to date achieve progenitor cell Increase in CD34 +
CD45RA -cells /DMSO (%)
expansion at the expense of the LT-HSC loss (6) , increasing the risk of late graft failure. Recent studies showed that aryl hydrocarbon receptor (AhR) antagonists and a notch ligand agonist promote the in vitro expansion of human CB cells, with repopulating activity lasting up to 16 weeks in immunodeficient mice (7, 8) . We developed an automated and continuous medium delivery system that produces an equivalent expansion of CB cells with similar repopulation properties (9) . This fed-batch culture system optimizes the balance of stimulatory and inhibitory factors in a small culture volume. We hypothesized that small molecules with potent LT-HSCstimulating activities might be identified and potentiated in this fed-batch culture system.
We screened a library of 5280 low-molecularweight compounds for their ability to expand human CD34 +
CD45RA
-mobilized peripheral blood (mPB) cells, which are enriched in LT-HSCs (10 More than 300 newly synthesized analogs of UM729 were examined, of which one (UM171, Fig. 1C ) was 10 to 20 times more potent than UM729, with effective concentrations of 17 to 19 nM when tested for its ability to stimulate the expansion of a HSC-enriched population, CD34 + CD45RA -cells (10) (Fig. 1D and fig. S3, A and B). UM729 did not expand mouse HSCs ( fig. S4 ). UM729 and UM171 treatment enhanced the engraftment potential of CD34 + macaque cells by threefold when compared with controls ( fig. S5 ).
Optimization of fed-batch culture duration indicated that the highest expansion of multipotent progenitors and long-term culture-initiating cells (LTC-ICs) was obtained on day 12 (fig. S3, C to E). Likewise, the proportion of apoptotic cells was lower at that time when compared with day 16 ( fig. S3F ). We also observed that the effect of UM171 requires its constant presence in the media and that the molecule lacks direct mitogenic activity ( fig. S6 ). Cell division tracking further showed that UM171 does not affect the division rate of phenotypically primitive populations ( fig. S7 ).
We next designed experiments to compare the impacts of UM171 and SR1 on outputs of CD34 + CB cells introduced in fed-batch cultures. Control (dimethyl sulfoxide, DMSO) fed-batch cultures contained mostly differentiated cells ( Fig colony-forming unit of granulocyte, erythrocyte, macrophage, megakaryocyte (CFU-GEMM) expansion (Fig. 2D ) and on mature cell output suppression (e.g., CD34 -cells in Fig. 2 , B and 2C) was enhanced by the addition of SR1. Together, these observations show that these two compounds cooperate to enhance ex vivo expansion of progenitor cells and that they suppress mature cell output (differentiation). These data also suggest that UM171 targets phenotypically more primitive cells than those targeted by SR1. By using conditions described in fig. S10A , we next determined the frequencies (adjusted to numbers of CD34 + cells at day 0, hereafter called d0 equivalent) and the absolute numbers of LTHSCs in fed-batch cultures supplemented with DMSO (control), UM171, SR1, or the combination of both (Fig. 3A and table S1, respectively) . When analyzed at 20 weeks posttransplantation, LT-HSC frequencies in fresh (uncultured) CD34 + CB were measured at the expected frequency of ∼1 per 880 CD34 + starting cells [95% confidence interval (CI) of 470 to 1600; see Fig. 3A in which frequencies (red line) and 95% CIs (gray box) are indicated]. Similar LT-HSC frequencies were obtained from fed-batch cultures (DMSO) whether or not they contained SR1 (Fig. 3A) . Frequencies of d0 equivalent LT-HSCs were 13-fold higher in cultures supplemented with UM171 when compared with DMSO or to fresh (uncultured) controls (Fig. 3A) . Absolute LT-HSC values determined after 20 weeks posttransplantation in all culture conditions are provided in table S1. Simultaneous addition of SR1 to UM171-treated cultures did not significantly change these numbers, indicating that the cooperativity between these two molecules is restricted to short-lived progenitors and that LT-HSC output is selectively enhanced in the presence of UM171 (Fig. 3A and  table S1 ).
We analyzed the nature of human hematopoietic reconstitution obtained by transplanting fresh or expanded cells in NOD scid gamma (NSG) mice. Levels of human cell engraftment, whether total (CD45), myeloid (CD33), or B lymphoid (CD19), were determined for~300 mice and represented in the form of a heat map in Fig. 3B (raw data in table S2). Analysis of this data set indicates two emerging patterns of human reconstitution, one from predominantly lymphomyeloid LT-HSCs, observed at high cell doses with most conditions, and the other from LT-HSCs that display a lymphoid-deficient differentiation phenotype mostly observed with UM171 treatment, with or without SR1 (Fig. 3B) DMSO   UM171   CD45  CD33  CD19  CD45  CD33  CD19  CD45  CD33  CD19  CD45  CD33  CD19  CD45  CD33 B lymphopoiesis nor the frequency or number of lymphomyeloid LT-HSCs is negatively affected by UM171 (Fig. 3B) . SR1 treatment appeared to compromise the in vivo proliferative potential, although not the number, of lymphomyeloid LT-HSCs (compare reconstitution levels of SR1 with uncultured or UM171 conditions in Fig. 3B ).
In support of this, the presence of SR1 in UM171 treated cultures appears to slightly hamper the proliferative potential of the expanded cells (see reduction in red in Combi versus UM171 conditions in Fig. 3B ). The impact of UM171 on LT-HSC was preserved at 30 weeks posttransplantation ( fig.  S10B and table S3 ), at which time multilineage contribution remained obvious at the high cell dose (Fig. 3C) . At this extended time point posttransplant, we also noted a slight augmentation in myeloid cell output, a phenomenon recently described with normal unexpanded cells (5, 13). The molecular and cellular mechanisms underlying this effect of UM171 on expanding LT-HSCs that show a lymphoid-deficient differentiation pattern are of interest given previous studies of a similar self-perpetuating LT-HSC subset in mice (14) whose prominence is increased in the bone marrow as soon as HSCs begin to migrate from the fetal liver to that site (15) .
To further evaluate the impact of UM171-treated LT-HSC population(s), we performed transplantation experiments in secondary recipients. For these studies, four to six primary recipients were selected per condition in which human reconstitution ranged between 10 and 70%. Results (table S4) indicate that UM171 ex vivo treatment did not appear to affect the capability of LT-HSC to expand in primary recipients and hence similarly reconstituted secondary animals for at least 18 more weeks, thus indicating that cells exposed to the molecule ex vivo are still competent in secondary recipients, where they show no advantage when compared to unmanipulated CD34 + cells. We next performed RNA sequencing (RNA-seq) expression profiling experiments to gain insights into the mode of action of UM171. SR1-treated cells were also analyzed for comparison. As expected, SR1 but not UM171 treatment resulted in downregulation of AhR target genes such as CYP1B1, CYP1A1, and AhRR (Fig. 4A and fig. S11A ) (7, 16) . Unlike SR1, UM171 treatment was accompanied by a marked suppression of transcripts associated with erythroid and megakaryocytic differentiation ( Fig. 4B and fig. S11B ). Only six to seven genes were commonly up-or down-regulated in cells exposed to UM171 or SR1 ( fig. S12A ). In line with these results, gene expression signatures were very different between cells exposed to UM171 versus those treated with SR1 ( fig. S11C  and fig. S12B ). Most notably, we found that the transmembrane protein of unknown function, TMEM183A, was the most up-regulated transcript in both conditions ( fig. S11, A and B) and that the most highly up-regulated genes in UM171-treated cells encode for surface molecules ( fig. S11B , highlighted in red). These genes include PROCR (also called EPCR or CD201), which represents a known marker of mouse LT-HSCs (17) . Additional RNAseq experiments and fluorescence-activated cellsorting (FACS) analyses confirmed that expression of this receptor is modulated, in a dose-dependent manner, by UM171 treatment (fig. S13 ).
UM171 enables a robust ex vivo expansion of human CB cells with functionally validated longterm in vivo repopulating capability (Fig. 4C) . On the basis of these findings, we suggest that UM171 acts by enhancing the human LT-HSC self-renewal machinery independently of AhR suppression. Conversely, AhR inhibitors' activity appears restricted to the production of cells with less-durable self-renewal activity (Fig. 4C) IRBIT is a novel regulator of ribonucleotide reductase in higher eukaryotes
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Ribonucleotide reductase (RNR) supplies the balanced pools of deoxynucleotide triphosphates (dNTPs) necessary for DNA replication and maintenance of genomic integrity. RNR is subject to allosteric regulatory mechanisms in all eukaryotes, as well as to control by small protein inhibitors Sml1p and Spd1p in budding and fission yeast, respectively. Here, we show that the metazoan protein IRBIT forms a deoxyadenosine triphosphate (dATP)-dependent complex with RNR, which stabilizes dATP in the activity site of RNR and thus inhibits the enzyme. Formation of the RNR-IRBIT complex is regulated through phosphorylation of IRBIT, and ablation of IRBIT expression in HeLa cells causes imbalanced dNTP pools and altered cell cycle progression. We demonstrate a mechanism for RNR regulation in higher eukaryotes that acts by enhancing allosteric RNR inhibition by dATP.
R ibonucleotide reductase (RNR) provides building blocks for genomic and mitochondrial DNA replication and repair, and uncontrolled RNR activity has been associated with malignant transformation and tumor cell growth. The key role of RNR in DNA synthesis has made it a target for both anticancer and antiviral therapy (1 
